{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:21:48Z","timestamp":1794547308562,"version":"4.9.1"},"reference-count":31,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Scientific and Technological Research Council of Turkey (T?BITAK)","award":["20AG007"],"award-info":[{"award-number":["20AG007"]}],"id":[{"id":"https:\/\/ror.org\/04w9kkr77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Scientific and Technological Research Council of Turkey (T?BITAK)","award":["20AG042"],"award-info":[{"award-number":["20AG042"]}],"id":[{"id":"https:\/\/ror.org\/04w9kkr77","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rational design of PEGylated protein therapeutics requires mechanistic understanding of how coupling chemistry and PEG size jointly determine product homogeneity, receptor engagement, and structural integrity\ue5f8the properties that collectively govern whether a conjugate is a viable candidate for further development. Anakinra (recombinant interleukin-1 receptor antagonist, IL-1Ra) is an approved anti-inflammatory biologic whose short systemic residence necessitates daily subcutaneous injection and is associated with steep peak\u2212trough exposure fluctuations that, in chronic high-dose regimens, have been linked to IL-1Ra-derived systemic amyloidosis. PEGylation offers a chemically established route to increase the apparent molecular size of IL-1Ra and thereby reduce renal filtration and smooth exposure, but the structural and functional consequences of conjugation have never been characterized at residue resolution for this target\ue5f8a gap that limits informed design choices between available chemistries. Here, we address this gap by establishing a head-to-head characterization framework comparing site-specific thiol-maleimide conjugation and random amino-coupling on a uniformly 15N-labeled recombinant IL-1Ra variant (M143V) that preserves all native conjugation sites and is potency-matched to Anakinra. Across a 5\u221220 kDa PEG ladder at a substoichiometric 0.5:1 PEG:protein feed, site-specific thiol-maleimide coupling yielded substantially higher conversion (\u223c81%) and a homogeneous single-species di-PEGylated (DoP 2) conjugate, whereas random amino-coupling produced heterogeneous mixtures across all PEG sizes (\u223c33\u221236% conversion, multiple degrees of polymerization). Purified single-species conjugates were benchmarked under a fixed IL-1\u03b2 EC80 challenge in HEK-Blue reporter cells; all retained full maximal efficacy but exhibited chemistry- and size-dependent right-shifts in IC50, indicating steric modulation of receptor engagement rather than loss of function. To directly establish whether PEG attachment perturbs structural integrity, 2D 1H\u221215N HSQC NMR on the 15N-labeled thiol-PEG10 conjugate demonstrated a preserved global fold with localized chemical-shift perturbations near cysteine-proximal surface regions, confirming site-selective modification and intact binding scaffold. Together, these data establish the conjugation quality, antagonist activity, and structural integrity of the lead conjugate as the prerequisite characterization foundation for its further development and provide a transferable analytical framework for the rational design of PEGylated cytokine therapeutics.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00060","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:27:59Z","timestamp":1782235679000},"page":"4820-4831","source":"Crossref","is-referenced-by-count":0,"title":["Structure-Guided PEGylation of IL\u20111Ra Preserves Fold and Antagonist Function"],"prefix":"10.1021","volume":"23","author":[{"given":"Is\u0327\u0131lay","family":"Go\u0308ktan","sequence":"first","affiliation":[{"name":"Koc\u0327 University , , Rumelifeneri Yolu , , ,","place":["Sariyer, Istanbul, Turkey, 34450"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1595-431X","authenticated-orcid":true,"given":"C\u0327ag\u030cdas\u0327","family":"Dag\u030c","sequence":"additional","affiliation":[{"name":"Koc\u0327 University , , Rumelifeneri Yolu , , ,","place":["Sariyer, Istanbul, Turkey, 34450"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Gu\u0308l","sequence":"additional","affiliation":[{"name":"Istanbul University Medical School , , Turgut O\u0308zal Millet Cd , , ,","place":["Fatih, Istanbul, Turkey, 34093"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-2698","authenticated-orcid":true,"given":"Seda","family":"Kizilel","sequence":"additional","affiliation":[{"name":"Koc\u0327 University , , Rumelifeneri Yolu , , ,","place":["Sariyer, Istanbul, Turkey, 34450"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"1","key":"2026100509322806700_cit1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/art.42664","article-title":"Anakinra-Associated Systemic Amyloidosis","volume":"76","author":"Alehashemi","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2026100509322806700_cit2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1461-5347(98)00086-8","article-title":"Polyethylene glycol-conjugated pharmaceutical proteins","volume":"1","author":"Bailon","year":"1998","journal-title":"Pharmaceutical Science & Technology Today"},{"issue":"7","key":"2026100509322806700_cit3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation","volume":"40","author":"Harris","year":"2001","journal-title":"Clinical Pharmacokinetics"},{"key":"2026100509322806700_cit4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.addr.2012.09.025","article-title":"Chemistry for peptide and protein PEGylation","volume":"64","author":"Roberts","year":"2012","journal-title":"Adv. Drug Delivery Rev."},{"issue":"5","key":"2026100509322806700_cit5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The Impact of PEGylation on Biological Therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"BioDrugs"},{"key":"2026100509322806700_cit6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-7643-8679-5_11","article-title":"PEGylation of human growth hormone: strategies and properties","volume-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","author":"Finn","year":"2009"},{"key":"2026100509322806700_cit7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-7643-8679-5_2","article-title":"Protein PEGylation, basic science and biological applications","volume-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","author":"Veronese","year":"2009"},{"issue":"25","key":"2026100509322806700_cit29","doi-asserted-by":"publisher","first-page":"14011","DOI":"10.1039\/C9RA00780F","article-title":"A Novel Method for PEGylation of Chitosan Nanoparticles through Photopolymerization","volume":"9","author":"Bozuyuk","year":"2019","journal-title":"RSC Adv."},{"key":"2026100509322806700_cit30","doi-asserted-by":"publisher","first-page":"110708","DOI":"10.1016\/j.colsurfb.2019.110708","article-title":"An All-Aqueous Approach for Physical Immobilization of PEG-Lipid Microgels on Organoid Surfaces","volume":"186","author":"Akolpoglu","year":"2020","journal-title":"Colloids Surf. B"},{"issue":"7","key":"2026100509322806700_cit31","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1089\/ten.tea.2009.0640","article-title":"Encapsulation of Pancreatic Islets within Nano-thin Functional Polyethylene Glycol Coatings for Enhanced Insulin Secretion","volume":"16","author":"Kizilel","year":"2010","journal-title":"Tissue Eng., Part A"},{"key":"2026100509322806700_cit8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-3-7643-8679-5_4","article-title":"Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation","volume-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","author":"Choi","year":"2009"},{"key":"2026100509322806700_cit9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-7643-8679-5_3","article-title":"Reactive PEGs for protein conjugation","volume-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","author":"Bonora","year":"2009"},{"issue":"7","key":"2026100509322806700_cit10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1039\/c1py00034a","article-title":"FDA-approved poly(ethylene glycol)-protein conjugate drugs","volume":"2","author":"Alconcel","year":"2011","journal-title":"Polym. Chem."},{"key":"2026100509322806700_cit11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01450","article-title":"From Synthesis to Characterization of Site-Selective PEGylated Proteins","volume":"10","author":"Bele\u0301n","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"9","key":"2026100509322806700_cit12","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1021\/acs.bioconjchem.2c00262","article-title":"Moving Protein PEGylation from an Art to a Data Science","volume":"33","author":"Mao","year":"2022","journal-title":"Bioconjugate Chem."},{"issue":"14","key":"2026100509322806700_cit13","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202200258","article-title":"Context-Dependence of the Reactivity of Cysteine and Lysine Residues","volume":"23","author":"Boll","year":"2022","journal-title":"Chembiochem"},{"issue":"2","key":"2026100509322806700_cit14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ejpb.2014.03.010","article-title":"Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra","volume":"87","author":"Liebner","year":"2014","journal-title":"Eur. J. Pharm. Biopharm"},{"issue":"2","key":"2026100509322806700_cit15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/jps.24253","article-title":"Head to Head Comparison of the Formulation and Stability of Concentrated Solutions of HESylated versus PEGylated Anakinra","volume":"104","author":"Liebner","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"2026100509322806700_cit16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/nano.2007.2.1.19","article-title":"Nanomedicines in the treatment of chronic hepatitis C-focus on pegylated interferon alpha-2a","volume":"2","author":"Thomas","year":"2007","journal-title":"Int. J. Nanomedicine"},{"issue":"12","key":"2026100509322806700_cit17","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.procbio.2009.07.010","article-title":"PEGylation of rhIL-1RA increased its solution stability at room temperature","volume":"44","author":"Yu","year":"2009","journal-title":"Process Biochemistry"},{"issue":"6","key":"2026100509322806700_cit18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.procbio.2007.03.003","article-title":"Facile purification of mono-PEGylated interleukin-1 receptor antagonist and its characterization with multi-angle laser light scattering","volume":"42","author":"Yu","year":"2007","journal-title":"Process Biochemistry"},{"key":"2026100509322806700_cit19","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1016\/j.bmc.2007.05.061","article-title":"Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist","volume":"15","author":"Yu","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"2026100509322806700_cit20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1353626","article-title":"Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)","volume":"15","author":"Li","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"38","key":"2026100509322806700_cit21","doi-asserted-by":"publisher","first-page":"39564","DOI":"10.1021\/acsomega.4c03610","article-title":"Characterizing the monomer-dimer equilibrium of UbcH8\/Ube2L6: A combined SAXS and NMR study","volume":"9","author":"Kahraman","year":"2024","journal-title":"ACS Omega"},{"issue":"7873","key":"2026100509322806700_cit22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"10","key":"2026100509322806700_cit23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nchem.2342","article-title":"Structure of a PEGylated protein reveals a highly porous double-helical assembly","volume":"7","author":"Cattani","year":"2015","journal-title":"Nat. Chem."},{"issue":"8","key":"2026100509322806700_cit24","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/chem.201804488","article-title":"Characterization of PEGylated Asparaginase: New Opportunities from NMR Analysis of Large PEGylated Therapeutics","volume":"25","author":"Cerofolini","year":"2019","journal-title":"Chem. Eur. J."},{"issue":"1","key":"2026100509322806700_cit25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ijpharm.2015.09.031","article-title":"Freeze-drying of HESylated IFN\u03b1-2b: Effect of HESylation on storage stability in comparison to PEGylation","volume":"495","author":"Liebner","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"8","key":"2026100509322806700_cit26","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3390\/pharmaceutics17081074","article-title":"Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization","volume":"17","author":"Fu","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026100509322806700_cit27","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1021\/acs.biomac.0c01627","article-title":"Polyglycerol for Half-Life Extension of Proteins-Alternative to PEGylation?","volume":"22","author":"Tully","year":"2021","journal-title":"Biomacromolecules"},{"issue":"1","key":"2026100509322806700_cit28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/acsbiomaterials.3c00636","article-title":"Molecular Dynamics Simulations for Rationalizing Polymer Bioconjugation Strategies: Challenges, Recent Developments, and Future Opportunities","volume":"10","author":"Kehrein","year":"2024","journal-title":"ACS Biomaterials Science & Engineering"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00060","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4820\/68745875\/mp6c00060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4820\/68745875\/mp6c00060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:20:08Z","timestamp":1794543608000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/4820\/5167802\/Structure-Guided-PEGylation-of-IL-1Ra-Preserves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,6,23]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00060","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00060.s002","asserted-by":"subject"}]},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}